PMID- 37746798
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230928
IS  - 2045-7022 (Print)
IS  - 2045-7022 (Electronic)
IS  - 2045-7022 (Linking)
VI  - 13
IP  - 9
DP  - 2023 Sep
TI  - Sensitivity to change and minimal clinically important difference of the 
      angioedema control test.
PG  - e12295
LID - 10.1002/clt2.12295 [doi]
LID - e12295
AB  - BACKGROUND: The Angioedema Control Test (AECT) is a patient-reported outcome 
      measure developed and validated for the assessment of disease control in patients 
      with recurrent angioedema. Its sensitivity to change and minimal clinically 
      important difference (MCID) have hitherto not been established. METHODS: Patients 
      with recurrent angioedema due to chronic spontaneous urticaria, hereditary 
      angioedema, or acquired C1-inhibitor deficiency were repeatedly asked to complete 
      the AECT along with the Angioedema Quality of Life Questionnaire (AE-QoL), 
      Dermatology Life Quality Index (DLQI), and anchors for disease control and 
      whether treatment was sufficient during routine care visits. The sensitivity to 
      the change of the AECT was determined by correlating changes in its scores over 
      time with changes in the applied anchors. The MCID was determined using 
      anchor-based and distributional criterion-based approaches. RESULTS: Eighty-six 
      cases were used for this analysis. Changes in AECT scores correlated well with 
      AE-QoL changes (but less with changes in the DLQI) as well as other applied 
      anchors, demonstrating its sensitivity to change. The MCID was found to be three 
      points for improvement of angioedema control. The available number of cases with 
      meaningful deterioration in our dataset was too low to reach a definite 
      conclusion on the MCID for deterioration of angioedema control. CONCLUSION: The 
      AECT is a valuable tool to assess changes in disease control in patients with 
      recurrent angioedema over time. The lowest AECT score change that reflects a 
      meaningful improvement of disease control to patients (MCID) is three points.
CI  - (c) 2023 The Authors. Clinical and Translational Allergy published by John Wiley & 
      Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
FAU - Fijen, Laure M
AU  - Fijen LM
AUID- ORCID: 0000-0002-0834-8138
AD  - Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam 
      UMC, University of Amsterdam, Amsterdam, The Netherlands.
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
FAU - Vera, Carolina
AU  - Vera C
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
FAU - Buttgereit, Thomas
AU  - Buttgereit T
AUID- ORCID: 0000-0002-9389-1767
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
FAU - Bonnekoh, Hanna
AU  - Bonnekoh H
AUID- ORCID: 0000-0002-3567-0149
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
FAU - Maurer, Marcus
AU  - Maurer M
AUID- ORCID: 0000-0002-4121-481X
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
FAU - Magerl, Markus
AU  - Magerl M
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
FAU - Weller, Karsten
AU  - Weller K
AD  - Institute of Allergology, Charite - Universitatsmedizin Berlin, corporate member 
      of Freie Universitat Berlin and Humboldt-Universitat zu Berlin, Berlin, Germany.
AD  - Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology 
      and Allergology, Berlin, Germany.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Clin Transl Allergy
JT  - Clinical and translational allergy
JID - 101576043
PMC - PMC10472988
OTO - NOTNLM
OT  - angioedema
OT  - disease control
OT  - minimal clinically important difference (MCID)7
OT  - patient-reported outcome measures (PROMs)
OT  - sensitivity to change
COIS- KW, MM and MM are advisors for Moxie. All other authors have no conflict of 
      interest regarding this manuscript.
EDAT- 2023/09/25 06:43
MHDA- 2023/09/25 06:44
PMCR- 2023/09/01
CRDT- 2023/09/25 05:33
PHST- 2023/07/20 00:00 [revised]
PHST- 2023/05/26 00:00 [received]
PHST- 2023/08/07 00:00 [accepted]
PHST- 2023/09/25 06:44 [medline]
PHST- 2023/09/25 06:43 [pubmed]
PHST- 2023/09/25 05:33 [entrez]
PHST- 2023/09/01 00:00 [pmc-release]
AID - CLT212295 [pii]
AID - 10.1002/clt2.12295 [doi]
PST - ppublish
SO  - Clin Transl Allergy. 2023 Sep;13(9):e12295. doi: 10.1002/clt2.12295.